Import and supply approved until:
15 May 2021
Section 19A approved medicine:
Furosemid-ratiopharm (Furosemide) 500mg tablet
Medicine in short supply/unavailable:
- UREX FORTE furosemide (frusemide) 500 mg tablet blister pack - ARTG 196972
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
Furosemide (Frusemide) in a high-dosage formulation is intended exclusively for patients with severely impaired renal function. For use under strict medical supervision only within a hospital setting (see Dosage and Administration). High doses of frusemide may be used as an adjuvant treatment of oliguria and in the promotion of diuresis in the treatment of oedema; in selected patients with acute renal failure, e.g. in the post-operative phase and in association with septic infections; in selected patients with chronic renal failure with fluid retention, both in the pre-dialysis phase and when dialysis has become unavoidable, especially in the presence of acute pulmonary oedema; in selected patients with the nephrotic syndrome with severe impairment of renal function e.g. in chronic glomerulonephritis, lupus erythematous and Kimmelstiel-Wilson syndrome. If diuresis is less than 2.5 L / day dialysis has to be used.
Import and supply approved until:
30 April 2021
Section 19A approved medicine:
Fluoxetine tablets USP 20mg (Dr Reddy's) 30 tablet bottle
Medicine in short supply/unavailable:
- Prozac Fluoxetine 20mg tablets - ARTG 61081 - Discontinued
- LOVAN TAB Fluoxetine (as hydrochloride) 20mg tablet blister pack - ARTG 61080
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
Treatment of Major depression and Obsessive Compulsive Disorder.
Import and supply approved until:
31 March 2021
Section 19A approved medicine:
NeoMercazole carbimazole 5mg tablets bottle of 50 (France)
Medicine in short supply/unavailable:
- Carbimazole Neo-Mercazole 5mg tablets bottle of 100 - ARTG 194296
Section 19A approval holder: Amdipharm Mercury (Australia) Pty Ltd
Approval holder phone number:
1800 627 680
Indications of the section 19A approved product
Therapy of hyperthyroidism. Definitive therapy: induction of a permanent remission, in either primary or secondary thyrotoxicosis. Preparation for thyroidectomy. Before and after radioactive iodine treatment.
Import and supply approved until:
31 January 2021
Section 19A approved medicine:
Tranylcypromine sulfate 10mg film coated tablets (Alvogen Inc)
Medicine in short supply/unavailable:
- PARNATE tranylcypromine (as sulphate) 10mg film coated tablet blister pack - ARTG 174086
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
Tranylcypromine sulfate is indicated for the treatment of symptoms of depressive illness especially where treatment with other types of antidepressants has failed. It is not recommended for use in mild depressive states resulting from temporary situational difficulties.
Import and supply approved until:
31 January 2022
Section 19A approved medicine:
Desmopressin Acetate Nasal Solution (Nasal Spray) 10mcg/0.1mL per spray 5mL bottle (Zydus Pharmaceuticals)
Medicine in short supply/unavailable:
- MINIRIN desmopressin acetate 10 microgram/ actuation nasal spray - ARTG 59320
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
- Diabetes Insipidus - The treatment of ADH-sensitive cranial diabetes insipidus, including treatment of post-hypophysectomy polydipsia and polyuria
Nocturnal Enuresis - The symptomatic treatment of primary nocturnal enuresis in patients who have normal ability to concentrate urine. Desmopressin Acetate Nasal Solution (Nasal Spray) 10mcg/0.1mL per spray (Zydus Pharmaceuticals) should be used only in patients who are refractory to the enuresis alarm or in patients in whom enuresis alarm is contraindicated or inappropriate, and where the oral administration of desmopressin is not feasible
Renal Concentrating Capacity - By intranasal administration to adults and children as a diagnostic test to establish renal concentrating capacity
Import and supply approved until:
31 October 2021
Section 19A approved medicine:
Mebrofenin kit for the preparation of Technetium Tc 99m mebrofenin for injection (USA)
Medicine in short supply/unavailable:
- HEPATOLITE kit for production of Technetium(99mTc) disofenin powder for injection multidose vial - ARTG 19146
Section 19A approval holder: Global Medical Solutions T/A Radpharm Scientific ABN 66 072 147 561
Approval holder phone number:
02 9503 8100
Indications of the section 19A approved product
Technetium Tc 99m Mebrofenin is indicated as an adjuct in the diagnosis of hepatobiliary disease.
Import and supply approved until:
30 April 2021
Section 19A approved medicine:
Fluoxetine capsules USP 20mg (ScieGen) 100 capsule bottle
Medicine in short supply/unavailable:
- PROZAC 20 fluoxetine 20mg (as hydrochloride) capsule - ARTG 14653
- LOVAN fluoxetine 20mg (as hydrochloride) capsule - ARTG 54700
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
Treatment of Major depression and Obsessive Compulsive Disorder
Import and supply approved until:
15 February 2021
Section 19A approved medicine:
TEVA-PRAZOSIN (Prazosin hydrochloride) 5mg tablets
Medicine in short supply/unavailable:
- MINIPRESS prazosin 5 mg (as hydrochloride) tablet blister pack - ARTG 10758
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
In Patients with Hypertension.
Indicated in the treatment of hypertension of varied aetiology and all grades of severity. It can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents.
Import and supply approved until:
15 February 2021
Section 19A approved medicine:
TEVA-PRAZOSIN (Prazosin hydrochloride) 2mg tablets
Medicine in short supply/unavailable:
- MINIPRESS prazosin 2 mg (as hydrochloride) tablet blister pack - ARTG 10757
- APO-PRAZOSIN prazosin (as hydrochloride) 2mg tablet blister pack - ARTG 73862
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
In Patients with Hypertension.
Indicated in the treatment of hypertension of varied aetiology and all grades of severity. It can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents.
Import and supply approved until:
15 February 2021
Section 19A approved medicine:
TEVA-PRAZOSIN (Prazosin hydrochloride) 1mg tablets
Medicine in short supply/unavailable:
- MINIPRESS prazosin 1 mg (as hydrochloride) tablet blister pack - ARTG 10756
Section 19A approval holder: Medsurge Healthcare Pty Ltd ABN 92 124 728 892
Approval holder phone number:
1300 788 261
Indications of the section 19A approved product
In Patients with Hypertension.
Indicated in the treatment of hypertension of varied aetiology and all grades of severity. It can be used as the initial and sole agent or it may be employed in a treatment programme in conjunction with other antihypertensive agents.
